Sun Pharmaceutical Industries Ltd
Fundamental Score
Sun Pharmaceutical Industries Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SUNPHARMA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (16.86%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.21%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (26.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Excellent EPS Growth (23.78% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (23.78% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (57.54x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹37510.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 36.67%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
1 factors identified
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Sun Pharmaceutical Industries Ltd
About SUNPHARMA
Business Overview
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Company Details
Key Leadership
Corporate Events
Latest News
SUNPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sun Pharmaceutical Industries Ltd (SUNPHARMA)?
As of 21 Jan 2026, 08:46 am IST, Sun Pharmaceutical Industries Ltd (SUNPHARMA) is currently trading at ₹1615.90. The stock has a market capitalization of ₹4.34L (Cr).
Is SUNPHARMA share price Overvalued or Undervalued?
SUNPHARMA is currently trading at a P/E ratio of 37.57x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Sun Pharmaceutical Industries Ltd share price?
Key factors influencing SUNPHARMA's price include its quarterly earnings growth (Sales Growth: 8.93%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sun Pharmaceutical Industries Ltd a good stock for long-term investment?
Sun Pharmaceutical Industries Ltd shows a 5-year Profit Growth of 23.78% and an ROE of 16.86%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.07 before investing.
How does Sun Pharmaceutical Industries Ltd compare with its industry peers?
Sun Pharmaceutical Industries Ltd competes with major peers in the Pharmaceuticals. Investors should compare SUNPHARMA's P/E of 37.57x and ROE of 16.86% against the industry averages to determine its competitive standing.
What is the P/E ratio of SUNPHARMA and what does it mean?
SUNPHARMA has a P/E ratio of 37.57x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹38 for every ₹1 of annual earnings.
How is SUNPHARMA performing according to Bull Run's analysis?
SUNPHARMA has a Bull Run fundamental score of 65.2/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SUNPHARMA belong to?
SUNPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sun Pharmaceutical Industries Ltd.
What is Return on Equity (ROE) and why is it important for SUNPHARMA?
SUNPHARMA has an ROE of 16.86%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Sun Pharmaceutical Industries Ltd generates profits from shareholders' equity.
How is SUNPHARMA's debt-to-equity ratio and what does it indicate?
SUNPHARMA has a debt-to-equity ratio of 0.07, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SUNPHARMA's dividend yield and is it a good dividend stock?
SUNPHARMA offers a dividend yield of 0.89%, which means you receive ₹0.89 annual dividend for every ₹100 invested.
How has SUNPHARMA grown over the past 5 years?
SUNPHARMA has achieved 5-year growth rates of: Sales Growth 9.87%, Profit Growth 23.78%, and EPS Growth 23.78%.
What is the promoter holding in SUNPHARMA and why does it matter?
Promoters hold 54.48% of SUNPHARMA shares, with 0.97% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SUNPHARMA's market capitalization category?
SUNPHARMA has a market capitalization of ₹433739 crores, placing it in the Large-cap category.
How volatile is SUNPHARMA stock?
SUNPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SUNPHARMA?
SUNPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is SUNPHARMA's operating profit margin trend?
SUNPHARMA has a 5-year average Operating Profit Margin (OPM) of 26.95%, indicating the company's operational efficiency.
How is SUNPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 8.93% and YoY Profit Growth of 2.56%.
What is the institutional holding pattern in SUNPHARMA?
SUNPHARMA has FII holding of 16.55% and DII holding of 20.12%. Significant institutional holding often suggests professional confidence in the stock.